- $7.35bn
- $6.72bn
- $36.13m
Brief: Merus’ Zeno Interim Data Continues To Demonstrate Robust And Durable Responses In Nrg1+ Cancer
Brief: Merus Announces Pricing Of Public Offering Of Common Shares
Brief: Merus Announces Proposed Public Offering Of Common Shares
Merus NV reports results for the quarter ended in June - Earnings Summary
Merus NV expected to post a loss of 87 cents a share - Earnings Preview
Brief: Merus' Zenocutuzumab Granted Breakthrough Therapy Designation By U.S. FDA
Brief: Zenocutuzumab Granted Breakthrough Therapy Designation By The U.S. Food & Drug Administration For The Treatment Of NRG1+ Pancreatic Cancer
Brief: Merus NV - Board Appointed Gregory Perry As CFO On June 14
Brief: Merus NV Entered Into Open Market Sale Agreement, On May 7, With Jefferies Llc To Sell Its Common Shares Of Up To $125 Million
Merus NV reports results for the quarter ended in March - Earnings Summary
Merus NV expected to post a loss of 96 cents a share - Earnings Preview
Merus NV expected to post a loss of 97 cents a share - Earnings Preview
Brief: Merus Announces Financial Results For The First Quarter 2023 And Provides Business Update
Merus gains on positive data from cancer therapy trial
Brief: Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity In Previously Treated Head And Neck Squamous Cell Carcinoma (Hnscc)
Brief: Merus Announces Publication Of An Abstract On Petosemtamab Monotherapy In Previously Treated Head And Neck Squamous Cell Carcinoma For Plenary Session Oral Presentation At The Aacr Annual Meeting 2023 And Provides A Program And Regulatory Update
Brief: Merus Announces Petosemtamab In Previously Treated Head And Neck Squamous Cell Carcinoma Abstract Selected For Plenary Session Oral Presentation At The Aacr Annual Meeting 2023
Merus NV reports results for the quarter ended in December - Earnings Summary
Brief: Merus NV Says FY Basic And Diluted Loss Per Share $2.92